Cancer DNA Detection in Blood and Urine (NCT02657863) | Clinical Trial Compass
CompletedNot Applicable
Cancer DNA Detection in Blood and Urine
United States61 participantsStarted 2014-11
Plain-language summary
This study is being conducted to collect and analyze biospecimens (blood and urine) and clinical data from patients with prostate cancer as well as healthy volunteers to better understand the differences between cancer cells and normal tissues with the goal of developing a better way to detect and track the treatment of prostate cancer.
* These samples are being collected to conduct research to accomplish the goal of improving cancer therapies, biomarkers, and hopefully lead to more effective treatment of prostate cancer.
* The samples that you are providing as a patient with prostate cancer will be used in future research.
* Your biospecimens will be compared to the cancer and normal volunteer specimens from other participants to understand genetic differences between normal and cancer cells. Genetic material, including DNA and RNA, will be obtained from samples, stored, and used for evaluation.
* Clinical information and samples will be collected and stored for ongoing research. This is a necessity because improved diagnosis, prognosis and treatment of cancer in the future depend upon the ongoing analysis of basic research findings and clinical outcomes. This type of research may improve the lives of future patients with cancer.
Men between the ages of 18 and 100 with a diagnosis of cancer undergoing standard therapy with radiation may join.
Who can participate
Age range
18 Years – 100 Years
Sex
MALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Male older than or equal to 18 years of age, but not older than 100 years of age.
. Signed informed consent prior to initiation of any study-related procedures.
. Minorities are included in this protocol.
. Signed informed consent prior to initiation of any study-related
Exclusion criteria
. It is the enrolling study physician's discretion to decide if a patient is not fit enough to undergo procedures outlined in this protocol.
. Persons who are incarcerated are not eligible to participate.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Healthy volunteer baseline
Timeframe: day 1
2
DNA alterations in blood and urine during radiation therapy
Timeframe: blood and urine draw at baseline, week 8 of treatment and then at week 16 of treatment
Trial details
NCT IDNCT02657863
SponsorSidney Kimmel Comprehensive Cancer Center at Johns Hopkins